Dr. Carpenter, as Editor-in-Chief of Schizophrenia Bulletin and a long-time researcher in the field, I’m sure you’ve seen trends come and go. Lately, we’ve been hearing a lot about how the older, conventional antipsychotics may be just as good as the newer atypicals. What’s your take?

You can't view details of this content, please login or buy subscription here